As seen in the blood on day 7 post-vaccination in both EG7 and B16.OVA tumor challenge experiments, the vaccination with Xcl1-(OVA SLP)-Fc fusion proteins plus CpG led to similar expansions of OVA-specific CTLs, which was best with Xcl1-(OVA SLP)-Fc, when compared to any other cohort, likely resulting from the co-delivery of the antigen to cross-presenting DCs via its fusion to Xcl1 (Figures 3C,D). Here, XCL1 is linked to neoplasm.